Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open-Label Extension Study of EFC12492, R727-CL-1112, EFC12732 and LTS11717 Studies to Assess the Long-Term Safety and Efficacy of Alirocumab in Patients With Heterozygous Familial Hypercholesterolaemia

X
Trial Profile

Open-Label Extension Study of EFC12492, R727-CL-1112, EFC12732 and LTS11717 Studies to Assess the Long-Term Safety and Efficacy of Alirocumab in Patients With Heterozygous Familial Hypercholesterolaemia

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 13 Jan 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alirocumab (Primary) ; Atorvastatin; Rosuvastatin; Simvastatin
  • Indications Hypercholesterolaemia; Hyperlipoproteinaemia type IIa
  • Focus Adverse reactions; Registrational
  • Acronyms ODYSSEY-OLE
  • Sponsors Sanofi
  • Most Recent Events

    • 07 Dec 2017 Status changed from active, no longer recruiting to completed.
    • 18 Nov 2017 This study has been completed in Portugal (End Date: 2017-06-30).
    • 15 Nov 2017 Results of analysis assessing long-term adherence to alirocumab and background lipid-lowering therapies during open label extension period presented at the 90th Annual Scientific Sessions of the American Heart Association
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top